10 results about "Piroxicam" patented technology

The invention relates to a method for detecting the concentration of Tongxekang, application and a device for detecting the concentration of Tongxekang drugs. According to the detection method provided by the invention, the concentration of the Tongxekang can be rapidly detected at a lower cost, the detection means is simple, the technical requirements on operators are lower, and the method is easier to popularize in a large range.

This invention discloses a piroxicam-containing solid dispersion and its preparation method. The piroxicam-containing solid dispersion of this invention constructs drug-carrier and carrier-carrier interactions from different dimensions, synergistically promoting the solubilizing ability of each carrier for the drug, improving the stability of the amorphous solid dispersion, and significantly increasing its apparent solubility. Furthermore, numerous in vivo experiments demonstrate that the quaternary system of the solid dispersion of this invention improves the bioavailability of piroxicam. The preparation technology of the piroxicam solid dispersion provided by this invention is simple, highly reproducible, and has good prospects for industrial production.

The invention relates to a carbon quantum dot, a preparation method, a detection method, and an application of XGBoost in identification of Tongxingkang components. The quantum dots provided by the invention can be subjected to fluorescence quenching through the Tongxikang class, fluorescence intensities corresponding to two excitation wavelengths of the quantum dots are reduced in an unequal proportion, and the type and concentration of the Tongxikang class can be determined to a certain extent through the ratio of the fluorescence intensities corresponding to the two excitation wavelengths. Based on the quantum dots provided by the invention, the XGBoost can effectively identify the specific types of the Tongxi Kang type. On the basis, based on the quantum dots provided by the invention, the CNN can further accurately identify the concentration of the Tongzhikang class. On the basis of cooperation of the two, low-cost and high-precision detection of the Tonxiakang class is realized.

The present invention provides a nucleoside derivative for preventing and treating inflammation and an application thereof in the preparation of a drug for preventing and treating inflammatory diseases. The nucleoside derivative for preventing and treating inflammation provided by the present invention can significantly ameliorate conditions of pancreatitis, hepatitis, arthritis and the like, ameliorate organ injury and inflammatory indexes, and have better effects than positive control drug, indometacin. Compared with the conventional anti-inflammatory drugs, aspirin, ibuprofen, indomethacin, phenylbutazone, diclofenac, piroxicam and glucocorticoids, the nucleoside derivative for preventing and treating inflammation provided by the present invention has the advantage of significantly fewer side effects.

This invention discloses a block-shaped piroxicam crystal and its direct compression formulation method, relating to the field of pharmaceutical formulation technology. The block-shaped piroxicam crystal is prepared according to the following steps: crude piroxicam is dissolved in a solvent, an organic acid and polyvinylpyrrolidone are added, the mixture is cooled and crystallized, and then filtered, washed, and dried to obtain block-shaped piroxicam crystals. The solvent is acetonitrile or ethyl acetate; the organic acid is glutaric acid or citric acid. The active pharmaceutical ingredient powder prepared by this invention has an angle of repose ≤35°, good flowability, which ensures smooth material transportation, mixing, and tableting processes, resulting in small tablet weight differences and high content uniformity. The finished tablet has a hardness ≥90 kgf, high mechanical strength, and a friability ≤0.02%, exhibiting extremely strong wear and breakage resistance, making it less prone to damage during production, packaging, and transportation. The 15-minute dissolution rate ≥50% balances formability and dissolution, facilitating rapid drug release and improving in vivo bioavailability.

The invention discloses a piroxicam ELISA (enzyme-linked immunosorbent assay) detection method and application thereof. The piroxicam hapten and the artificial antigen are provided, the monoclonal antibody of piroxicam is prepared, the piroxicam detection sensitivity is high, the lowest detection limit LOD is 0.52 ng / mL, the half inhibitory concentration IC50 is 10.94 ng / mL, the quantitative detection range is 1.61-74.31 ng / mL, the specificity is high, and no obvious cross reaction exists between the piroxicam hapten and the artificial antigen and similar drugs of piroxicam.

The utility model relates to the technical field of piroxicam methylate, in particular to a piroxicam methylate crude product refining device which comprises a base, a crystallizing tank fixedly mounted at the top of the base through a plurality of supporting legs, a refrigerating mechanism mounted on the outer side surface of the crystallizing tank, a top cover mounted at the top of the crystallizing tank, and a second rotating shaft rotationally connected to the top of the top cover, the second rotating shaft extends into the crystallizing tank, a spiral blade is installed on the side face of the second rotating shaft, and a first driving motor is installed at the top of the top cover. The first driving motor can drive the spiral blade to rotate, a solution at the bottom of the crystallizing tank is conveyed to the top of the crystallizing tank, meanwhile, the first rotating shaft can rotate along with the second rotating shaft under the action of the first gear and the second gear, and then the stirring blade stirs the solution in the crystallizing tank; therefore, the solution is uniformly cooled, and the crystallization effect is improved.

The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to a new crystal form of piroxicam, a preparation method and application thereof, wherein the X-ray diffraction pattern of the new crystal form of piroxicam has characteristic diffraction peaks at the following 2θ angles: 7.00°, 7.30°, 8.78°, 9.80°, 12.34°, 13.63°, 14.25°, 15.26°, 15.70°, 15.84°, 16.84°, 17.31°, 17.64°, 18.32°, 19.01°, 20.51°, 20.78°, 21.76°, 22.61°, 23.80°, 24.55°, 25.40°, 28.18°, with an error of ±0.1°. The preparation method of the new crystal form of piroxicam is simple, and the crystal of the new crystal form of piroxicam has good mechanical elasticity and tabletting performance.

The present invention relates to carbon quantum dots, preparation methods, detection methods, and the application of XGBoost in the identification of piroxicam-like ingredients. Piroxicam can cause fluorescence quenching in the quantum dots provided by the present invention, resulting in a non-proportional decrease in the fluorescence intensity corresponding to two excitation wavelengths. The ratio of the fluorescence intensities corresponding to the two excitation wavelengths can, to a certain extent, determine the type and concentration of piroxicam. Based on the quantum dots provided by the present invention, XGBoost can effectively identify the specific type of piroxicam. Furthermore, a CNN based on the quantum dots provided by the present invention can further accurately identify the concentration of piroxicam. This combination of XGBoost and XGBoost enables low-cost, high-precision detection of piroxicam-like ingredients.

The invention relates to the technical field of medicines, in particular to a traditional Chinese medicine pill for treating high uric acid and a preparation process thereof. The invention provides a traditional Chinese medicine pill for treating high uric acid. The traditional Chinese medicine composition is characterized by comprising the following components in percentage by weight: 5% of curcuma zedoary, 4% of immature bitter orange, 2% of golden cypress, 3% of poria cocos, 4% of astragalus membranaceus, 3% of cinnamon, 2% of cowherb seed, 2% of gallnut, 2% of clove, 2% of rheum officinale, 2% of sappan wood, 4% of ligusticum wallichii, 3% of honeysuckle, 1.5% of scorpio, 2% of liquorice, 2% of fructus cnidii, 1.5% of asarum, 0.05% of diclofenac, 0.05% of piroxicam, 14.9% of honey and 40% of syrup. The preparation method has the beneficial effects that the preparation process is reasonable: in the preparation process, the weighing precision of each raw material is strictly controlled, so that the accuracy of the formula is ensured; appropriate crushing meshes and a low-temperature crushing process are adopted, so that the dissolution rate of the medicine is improved, and effective components are reserved; an equivalent progressive increase mixing method and a three-dimensional mixing machine are adopted in the mixing process, so that all the components are uniformly mixed; and controlling the hardness of the soft material and the specification of the pill in the pill making process.